EUVIMEDEUVIMED entdecken
Open Access

TREM2 deficiency reprograms intestinal macrophages and microbiota to enhance anti–PD-1 tumor immunotherapy

Blanda Di Luccia iD, Martina Molgora iD, Darya Khantakova iD, Natalia Jaeger iD, Hao-Wei Chang iD, Rafael S Czepielewski iD, Beth A Helmink iD, Emily J Onufer iD, José L Fachi iD, Bishan Bhattarai, Tihana Trsan iD, Patrick F Rodrigues iD und 8 weitere

Science Immunology · 17.05.2024 · 9 (95)

DOI: 10.1126/sciimmunol.adi5374 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Immunology, erschienen am 17.05.2024. Verfasst von Blanda Di Luccia und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Immunology, Washington University School of Medicine in Saint Louis, St. Louis, MO 63110, USA. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Immunotherapy, Macrophages, Membrane Glycoproteins. Die Arbeit wurde bisher 65-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NCI NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The gut microbiota and tumor-associated macrophages (TAMs) affect tumor responses to anti–programmed cell death protein 1 (PD-1) immune checkpoint blockade. Reprogramming TAM by either blocking or deleting the macrophage receptor triggering receptor on myeloid cells 2 (TREM2) attenuates tumor growth, and lack of functional TREM2 enhances tumor elimination by anti–PD-1. Here, we found that anti–PD-1 treatment combined with TREM2 deficiency in mice induces proinflammatory programs in intestinal macrophages and a concomitant expansion of Ruminococcus gnavus in the gut microbiota. Gavage of wild-type mice with R. gnavus enhanced anti–PD-1–mediated tumor elimination, recapitulating the effect occurring in the absence of TREM2. A proinflammatory intestinal environment coincided with expansion, increased circulation, and migration of TNF-producing CD4 + T cells to the tumor bed. Thus, TREM2 remotely controls anti–PD-1 immune checkpoint blockade through modulation of the intestinal immune environment and microbiota, with R. gnavus emerging as a potential probiotic agent for increasing responsiveness to anti-PD-1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal MicrobiomeImmunotherapyMacrophagesMembrane GlycoproteinsMice, Inbred C57BLProgrammed Cell Death 1 ReceptorReceptors, ImmunologicAnimalsMiceImmune Checkpoint InhibitorsIntestinesMice, Knockout

Substanzen

Immune Checkpoint InhibitorsMembrane GlycoproteinsPdcd1 protein, mouseProgrammed Cell Death 1 ReceptorReceptors, ImmunologicTrem2 protein, mouse

Autor:innen und Institutionen

  • Department of Pathology and Immunology, Washington University School of Medicine in Saint Louis, St. Louis, MO 63110, USA.
  • Department of Microbiology and Immunology, Stanford University, Stanford, CA 94305, USA.
  • Edison Family Center for Genome Sciences and Systems Biology, Washington University School of Medicine, St. Louis, MO 63110, USA.
  • Department of Surgery, Washington University School of Medicine, St. Louis, MO 63110, USA.
  • Center for Gut Microbiome and Nutrition Research, Washington University School of Medicine, St. Louis, MO 63110, USA.

ORCID-Profile: Blanda Di Luccia, Martina Molgora, Darya Khantakova, Natalia Jaeger, Hao-Wei Chang, Rafael S Czepielewski, Beth A Helmink, Emily J Onufer, José L Fachi, Tihana Trsan, Patrick F Rodrigues, JinChao Hou, Jennifer K Bando, Cristiane Sécca da Silva, Marina Cella, Susan Gilfillan, Robert D Schreiber, Jeffrey I Gordon, Marco Colonna

Förderung

  • NIDDK NIH HHS
  • NCI NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Di Luccia, B., Molgora, M., Khantakova, D., Jaeger, N., Chang, H. W., Czepielewski, R. S., Helmink, B. A., Onufer, E. J., Fachi, J. L., Bhattarai, B., Trsan, T., Rodrigues, P. F., Hou, J., Bando, J. K., da Silva, C. S., Cella, M., Gilfillan, S., Schreiber, R. D., Gordon, J. I., & Colonna, M. (2024). TREM2 deficiency reprograms intestinal macrophages and microbiota to enhance anti–PD-1 tumor immunotherapy. Science Immunology, 9(95). https://doi.org/10.1126/sciimmunol.adi5374

Vancouver

Di Luccia B, Molgora M, Khantakova D, Jaeger N, Chang HW, Czepielewski RS, et al. TREM2 deficiency reprograms intestinal macrophages and microbiota to enhance anti–PD-1 tumor immunotherapy. Science Immunology. 2024;9(95). doi:10.1126/sciimmunol.adi5374

BibTeX
@article{DiLuccia2024,
  author = {Di Luccia, Blanda and Molgora, Martina and Khantakova, Darya and Jaeger, Natalia and Chang, Hao-Wei and Czepielewski, Rafael S and Helmink, Beth A and Onufer, Emily J and Fachi, José L and Bhattarai, Bishan and Trsan, Tihana and Rodrigues, Patrick F and Hou, JinChao and Bando, Jennifer K and da Silva, Cristiane Sécca and Cella, Marina and Gilfillan, Susan and Schreiber, Robert D and Gordon, Jeffrey I and Colonna, Marco},
  title = {TREM2 deficiency reprograms intestinal macrophages and microbiota to enhance anti–PD-1 tumor immunotherapy},
  journal = {Science Immunology},
  year = {2024},
  volume = {9},
  number = {95},
  doi = {10.1126/sciimmunol.adi5374}
}
Kostenlos starten →